Emerging Treatment Approaches and Multidisciplinary Management of Unresectable Stage III Non-Small Cell Lung Cancer

EP. 1: Defining Resectability in Stage III NSCLC: Addressing Key Controversies

December 24th 2024

Panelists discuss how the resectability of stage III non-small cell lung cancer tumors remains controversial, particularly regarding the role of surgery in multi-station N2 disease and the optimal sequencing of multimodality therapy.

EP. 2: Multidisciplinary Strategies for Optimizing Care in Unresectable Stage III NSCLC

January 21st 2025

This video segment discusses defining resectability for Stage III lung cancer, the importance of a multidisciplinary approach to decision-making involving surgical, medical, radiation oncology, and diagnostic teams, and the role of patient engagement in tailoring treatment plans to individual priorities, risks, and physiological suitability.

EP. 3: Optimizing Biomarker Testing for Unresectable Stage III NSCLC

January 21st 2025

This segment explores the role of biomarker testing in optimizing outcomes for non-small cell lung cancer (NSCLC), highlighting challenges in early-stage testing, the importance of multidisciplinary collaboration, and recent advances like the LAURA trial that emphasize the need for comprehensive biomarker assessment.

EP. 4: Overcoming Barriers to Biomarker Testing in Unresectable NSCLC: Strategies for Improved Access and Implementation

January 21st 2025

This segment discusses the importance of biomarker testing in lung cancer, challenges in implementation such as tissue adequacy and result delays, and strategies to enhance testing in both academic and community settings through local champions and education.